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[[ABSTRACT [limit: 250 words; current count: 244]] 
Background: Amphotericin B deoxycholate (AmB-D) is standard of care treatment for neonatal 
invasive candidiasis (IC). Micafungin (MCA) has broad-spectrum fungicidal activity against 
Candida spp. We compared the efficacy and safety of intravenous MCA with intravenous AmB-
D and assessed the pharmacokinetics (PK) of MCA in infants aged >2–120 days with proven IC 
in a phase 3, randomized, double-blind, multicenter, parallel-group, noninferiority study 
(NCT00815516).  
Methods: Infants were randomized 2:1 to MCA (10 mg/kg/day) or AmB-D (1 mg/kg/day) for 
≥21 days. Primary efficacy endpoint was fungal-free survival (FFS) 1 week after last study drug 
dose. MCA population PK included simulated steady-state AUC (AUCss) and maximum plasma 
concentration after 2-hour infusion (C2hr). AUC pharmacodynamic (PD) target exposure was 170 
µg·h/mL. 
Results: Thirty infants received MCA (n=20) or AmB-D (n=10). The trial was terminated early 
due to slow recruitment. FFS was observed in 12 of 20 (60%; 95% CI, 36–81%) MCA-group 
infants and in 7 of 10 (70%; 95% CI, 35–93%) AmB-D-group infants. The most common 
treatment-emergent adverse events were anemia (MCA: n=9 [45%]; AmB-D: n=3 [30%]) and 
thrombocytopenia (n=2 [10%] and n=3 [30%], respectively). Model-derived mean AUCss for 
MCA was 399.3 ± 163.9 µg·h/mL (95% prediction interval [PI]: 190.3–742.3 µg/mL); C2hr was 
31.1 ± 10.5 µg/mL (95% PI: 17.0–49.7 µg/mL). MCA exposures were above the AUC PD target 
exposure.  
Conclusions: Within the study limitations, infants with IC treated with MCA achieved similar 
FFS compared with AmB-D. Both agents were safe and well tolerated. 
Key Words: amphotericin B deoxycholate, infants, invasive candidiasis, micafungin, neonates 
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INTRODUCTION 
Invasive candidiasis (IC) is a cause of significant morbidity and mortality in hospitalized 
infants
1-3
 and can result in severe neurodevelopmental impairment.
4
 Treatment-refractory IC can 
occur in infancy despite the use of conventional antifungal therapy with amphotericin B or 
fluconazole.
5
 There is a paucity of data on the efficacy, safety, and pharmacokinetics (PK) of 
antifungal agents for the treatment of neonatal IC due to technical challenges and ethical issues. 
Direct extrapolation of data from studies in adults is not appropriate due to differences in PK and 
pharmacodynamics (PD). Nonetheless, several antifungal agents are used clinically, and agents 
recommended by infectious disease advisory boards for the treatment of neonatal IC include 
amphotericin B deoxycholate (AmB-D), liposomal amphotericin B, amphotericin B lipid 
complex, fluconazole, and the echinocandins micafungin (MCA) and caspofungin.
6,7
 To date, no 
infectious disease expert bodies have recommended a specific antifungal agent for neonatal use; 
however, AmB-D, fluconazole, and MCA are considered as the current therapeutic agents of 
choice for the treatment of IC in infants.
6,8,9
  
 AmB-D has been the standard of treatment for neonatal IC in the United States for many 
years,
7
 but nephrotoxicity is a dose-limiting toxicity.
10
 Amphotericin B formulations have not 
been optimized for use in infants, and limited available data suggest that AmB-D exhibits 
considerable PK variability between infants.
11,12
 The use of fluconazole in infants may be limited 
due to the resistance of some Candida spp., its frequent use as prophylaxis in extremely 
premature infants, its poor activity against fungal biofilms, and the high doses required to reach 
therapeutic concentrations.
9,13-15
 In contrast, the echinocandins are broad-spectrum antifungal 
agents, of which MCA is the most studied in infants and is active against biofilms as well as 
fluconazole-resistant Candida spp.
16,17
 The recommended dose regimen in adults is 100 mg/day 
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(approximately 2 mg/kg), which has a mean exposure of 100 µg·h/mL in adults, although an in 
vivo rabbit model of hematogenous Candida meningoencephalitis (HCME) suggested a higher 
AUC target of 170 µg·h/mL is necessary to adequately treat central nervous system (CNS) 
candidiasis.
18
 PK bridging studies conducted in infants ≤4 months of age19 suggested that the use 
of MCA at doses of 10 mg/kg/day is sufficient to reach the PD target in infants. PK and safety 
studies have demonstrated that MCA doses of up to 15 mg/kg/day are safe and well tolerated in 
young infants, offering exposure levels that are adequate to treat end-organ dissemination, 
including HCME.
18-20
 MCA is currently the only antifungal agent approved for neonatal use in 
the European Union,
21
 and in the United States it is approved for the treatment of IC and 
candidemia in children ≥4 months old.22  
 Little is known about the comparative efficacy, safety, and tolerability of MCA versus 
AmB-D in the treatment of neonatal IC. Herein, we report the efficacy and safety of MCA 
compared with AmB-D for the treatment of proven neonatal IC from a phase 3 study. A 
population PK analysis of MCA was also performed. 
MATERIALS AND METHODS 
Study Design and Patients 
This was a phase 3, randomized, double-blind, multicenter, parallel-group, noninferiority study 
(ClinicalTrials.gov identifier: NCT00815516) comparing the efficacy and safety of intravenous 
MCA with intravenous AmB-D as treatment for IC in infants, and assessing the PK of 
intravenous MCA. Infants >2–120 days of life at the time of culture acquisition with proven IC 
were enrolled and randomized 2:1 to MCA or AmB-D. MCA was administered at 10 mg/kg/day 
and AmB-D was dosed at 1 mg/kg/day for a minimum of 21 days,
23
 and for a maximum of 28 
days or 42 days in infants without or with end-organ dissemination, respectively. The dose 
AC
CE
PT
ED
6 
 
rationale for MCA was based on data from previous preclinical and clinical studies.
18,20
 Each 
infant was assessed for 30 days following the last dose of study drug. The follow-up was 
performed to capture emergent and recurrent fungal infections, to obtain a final safety 
evaluation, and to check for resolution of those IC episodes that had not resolved by end of 
treatment. An end of study visit was performed 30 days after the final dose of study drug. An 
independent Data Review Panel reviewed and confirmed the diagnosis of IC and evaluated the 
efficacy outcome for each subject. Drug safety was evaluated by an unblinded Data Safety and 
Monitoring Board.  
 A diagnosis of IC required 1 of the following criteria to be met ≤4 days prior to the first 
dose of study drug: a positive blood culture collected for proven candidemia; a positive urine 
fungal culture by in and out (I/O) catheterization (≥103 colony-forming units [CFU]/mL in a 
single urine culture) or suprapubic aspiration (≥102 CFU/mL in a single urine culture) for proven 
candiduria; the presence of Candida spp. in cerebrospinal fluid (CSF) for proven Candida 
meningitis; either a positive tissue biopsy or culture from a normally sterile body fluid (ie, blood, 
urine, or CSF); or a positive culture for Candida (or yeast) obtained from a new drain (≤7 days 
prior to first dose of study drug) from a normally sterile site.  
 Exclusion criteria included any history of hypersensitivity or severe vasomotor reaction 
to any echinocandin or systemic amphotericin B product, receipt of >48 hours of systemic 
antifungal therapy prior to treatment for IC, or breakthrough systemic fungal infection while 
receiving an amphotericin B product or an echinocandin as prophylaxis. In addition, infants who 
had previously failed systemic antifungal therapy for the current IC episode, including 
recurrence of the same Candida infection within 2 weeks of completing systemic antifungal 
treatment, were excluded, as were those who were co-infected with a non-Candida fungal 
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organism or whose positive yeast cultures were solely from an indwelling bladder catheter or 
sputum, or with a concomitant medical condition that might create unacceptable additional risk 
in the opinion of the investigator and/or medical advisor.  
 The parent/legal guardian provided written informed consent. The study received 
approval from the Institutional Review Board/Independent Ethics Committee at each site and 
was conducted in accordance with the International Conference on Harmonisation Guidelines for 
Good Clinical Practice. 
Efficacy Assessments 
The primary efficacy endpoint was fungal-free survival (FFS) 1 week after the last dose of the 
study drug, irrespective of treatment discontinuation. Fungal-free survival was defined as an 
infant alive and fungal free with no requirement for continued treatment with alternative 
antifungal therapy. Secondary efficacy variables included clinical response of infants with 
clinical signs and symptoms of fungal infection at baseline and at 1 week after the last dose of 
study drug, mycological response at the end of study drug therapy and at 1 week after the last 
dose of study drug, and the frequency of emergent and recurrent fungal infections through the 
end of study.  
 Attributable signs related to fungal infection were assessed during screening, and clinical 
response was assessed weekly while on study drug therapy, at 1 week after the last dose of study 
drug, and at the end of study visit. Responses were defined as: complete response (resolution of 
all attributable signs related to fungal infection); partial response (improvement in attributable 
signs related to the fungal infection); stabilization (minor improvement or no change in 
attributable signs related to the fungal infection and the infant continued on therapy without 
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deterioration); progression (deterioration in attributable signs related to the fungal infection or 
death presumably related to fungal infection).  
 Mycological response was assessed at the end of study drug therapy and 1 week after the 
last dose of study drug. Eradication was indicated by culture or the histologically documented 
absence of the infecting Candida spp. from all previously positive, normally sterile sites during 
therapy (2 negative samples collected ≤24 hours apart or 1 negative culture for Candida 
meningitis and/or candiduria, with no sign of fungal growth on culture ≤72 hours of collection). 
Persistence was defined by continued isolation or histological documentation from a normally 
sterile site. Blood and urine fungal cultures were requested to be performed every 48 hours until 
2 negative cultures were obtained, separated by ≥24 hours. When CSF culture was positive, 
repeat lumbar puncture was to be repeated every 4 to 7 days until negative culture was 
documented. 
 Following positive Candida cultures, end-organ dissemination was assessed using 
abdominal ultrasound and/or computed tomography (CT) scanning, echocardiogram, head 
imaging with ultrasound, magnetic resonance imaging or CT scanning, or ophthalmoscopy. An 
emergent fungal infection was defined as a non-Candida invasive fungal infection detected at 
any time during the study or any invasive fungal infection detected >96 hours post-baseline 
involving a Candida spp. other than those detected at baseline. Recurrent infection was defined 
as a systemic fungal infection with eradication on or before the end of study drug therapy but 
reappearing within 1 week later, in infants who developed positive blood cultures or a 
mycologically confirmed deep-seated Candida infection of the same species as that causing the 
infection at enrollment. 
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 All fungal isolates were identified to the genus and species level using standard 
techniques. Briefly, each isolate was sub-cultured in CHROMagar™ Candida (Becton Dickinson 
and Company, Sparks, Maryland) and molecular identification by sequencing of the internal 
transcribed spacer region and/or 28S ribosomal subunit. In vitro susceptibility testing was 
performed on all fungal isolates collected during the study to calculate the minimum inhibitory 
concentrations (MIC) according to Clinical Laboratory Standards Institutes (CLSI) methodology 
(M27-A3) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) 
methodology (EDef7.1).
24,25
 
Pharmacokinetics Analysis 
Up to three PK blood samples (≤300 µL) were collected from infants who participated in the PK 
portion of the study. A population PK approach was used to define the PK profile of MCA. A 
linear two-compartment population PK model with body weight-based allometric scaling was 
developed in neonatal and pediatric patient populations by amending a previous model
19,26
 and 
including data from the current study in addition to 2 previous phase 1 studies and 1 previous 
phase 3 study in infants.
20,27,28
 Individual post-hoc estimates of PK parameters, simulated steady-
state AUC (AUCss), and maximum plasma concentration at the end of 2-hour infusion (C2hr) at 
once-daily dose of MCA 10 mg/kg were derived based on the model. AUC PD target exposure 
was 170 µg·h/mL based on an in vivo rabbit model of HCME.
18
 
Safety Assessments 
Adverse events, biochemical and hematological laboratory parameters, and survival were 
assessed for all infants who received at least 1 dose of study drug. Treatment-emergent adverse 
events (TEAEs), defined as AEs occurring from the first dose of the study drug through 72 hours 
after the last dose, were summarized by treatment group. Nephrotoxicity was potentially a key 
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difference between the study drugs, which was defined as >25%, >50%, and >100% change from 
baseline in serum creatinine. 
Statistical Analyses 
Based on an estimated treatment success rate of 75%,
29
 a planned sample size of 225 infants was 
estimated to provide ≥90% power to demonstrate the noninferiority of MCA to AmB-D at a 
2.5% significance level using a margin of 20%. For the primary efficacy analysis, which used the 
full analysis set (all randomized infants who were administered any amount of study drug), it 
was planned that a 2-sided 95% confidence interval (CI) would be constructed for the difference 
in success rates between MCA and AmB-D, based on the Cochran-Mantel-Haenszel method 
adjusting for estimated gestational age (<27 weeks, ≥27 weeks) and geographic region (North 
America/Europe, Latin America, and other region). The safety analysis set included all 
randomized infants who received at least 1 dose of study drug. Demographic and baseline 
characteristics, secondary endpoints, and safety endpoints were descriptively summarized by 
treatment group. Statistical analyses were performed using SAS
®
 version 9.1.3 (SAS Institute, 
Inc., Cary, North Carolina). 
RESULTS 
Patient Demographics and Baseline Characteristics 
The trial was conducted between February 23, 2013 and December 15, 2014 at 71 study centers 
in 23 countries. The trial was terminated prior to completion after 2 years and 5 months due to 
slow recruitment (including time from opening of first study center to screening [May 2012] 
until study termination [October 2014]). However, 30 infants were randomized and received 
study drug (MCA: n = 20; AmB-D: n = 10). Patient demographics and baseline characteristics 
are summarized in (Table, Supplemental Digital Content 1, http://links.lww.com/INF/D95). In 
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both treatment groups, the most common comorbid conditions identified at baseline were 
respiratory distress, anemia, and hyperbilirubinemia. The most common organisms were 
Candida albicans in 13 (41%) infants and Candida parapsilosis in 11 (34%) infants. 
Study Completion 
Eleven (55%) MCA-treated infants and 4 (40%) AmB-D-treated infants completed the treatment 
period. The mean ± standard deviation (SD) treatment duration was 18.6 ± 10.7 days and 15.5 ± 
11.2 days for the MCA and AmB-D treatment groups, respectively.   
 Overall, 9 (45%) infants discontinued treatment early with MCA and 6 (60%) infants 
discontinued treatment early with AmB-D. Reasons for early discontinuation of treatment 
included AEs (MCA: 3 [15%]; AmB-D: 3 [30%]), physician decision (MCA: 3 [15%]; AmB-D: 
0), death (MCA: 2 [10%]; AmB-D: 0), lack of efficacy (MCA: 1 [5%]; AmB-D: 1 [10%]), or 
protocol violation (MCA: 0; AmB-D: 2 [20%]). Physician decisions for discontinuing treatment 
with MCA included persistence of infection despite treatment (n = 1), protection of the subject’s 
best interests (n = 1), and a decision to switch treatment to another antifungal agent not used in 
the present study (n = 1). Sixteen (80%) MCA-treated infants and 9 (90%) AmB-D-treated 
infants completed follow-up. Four (20%) MCA-treated infants discontinued the study before the 
follow-up visit due to death in 3 (15%) infants, and physician decision based on the infant’s best 
interests in 1 (5%) infant. One (10%) AmB-D-treated infant discontinued the study due to death. 
Eleven infants received alternative systemic antifungal treatment after discontinuation of study 
treatment (MCA group, n=4; AmB-D group, n=7). In 2 of those infants (1 each in MCA and 
AmB-D groups), the alternative systemic antifungal treatments were initiated >48 hours after 
discontinuation of the study drug. 
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Efficacy Outcomes 
The primary efficacy outcome of FFS at 1 week after the last dose of study drug was observed in 
12 (60%; 95% CI, 36–81%) infants in the MCA group and in 7 (70%; 95% CI, 35–93%) infants 
in the AmB-D group (Table 1). An additional 5 (25%) infants in the MCA group and 2 (20%) 
infants in the AmB-D group were alive at 1 week after the last dose of study drug, but were not 
fungal free and, therefore, did not meet the criteria for the primary efficacy end point. Of the 5 
infants in the MCA group who were alive at 1 week after the last dose, 2 infants had at least 1 
negative culture before the 1-week follow-up visit. One of 2 infants in the AmB-D group had 1 
negative culture.  
 Secondary efficacy outcomes are summarized in Table 1. Of the 18 infants in the MCA 
group and 10 infants in the AmB-D group with clinical signs and symptoms of fungal infection 
at baseline, 11 infants (61%; 95% CI, 36–83%) compared with 7 infants (70%; 95% CI, 35–
93%), respectively, had a positive clinical response at the end of the study and 1 week after the 
last dose of study drug. Eleven (55%; 95% CI, 32–77%) and 8 (80%; 95% CI, 44–98%) of 
MCA- and AmB-D-treated infants, respectively, achieved eradication at end of study drug 
therapy and 1 week after the last dose of study drug. One infant in the MCA group was deemed 
by the Data Review Panel as having met the primary efficacy outcome but had only one culture-
negative sample collected during treatment and so eradication was not confirmed.  
 Persistent fungal infection occurred in 2 (10%) infants in the MCA and in 2 (20%) infants 
in the AmB-D groups, respectively. The persistent infections were due to Candida parapsilosis 
in both MCA-treated infants and Candida glabrata and Candida albicans in AmB-D-treated 
infants (Table 1). The MCA MICs of the baseline isolates for the 2 persistent infections in the 
MCA group were 1 mg/L (CLSI and EUCAST methodologies) for one infection and 1 mg/L 
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(CLSI) and 0.5 mg/L (EUCAST) for the other infection (within the CLSI susceptible criteria for 
Candida parapsilosis of ≤2 mg/L, and between the EUCAST susceptible and resistant 
breakpoints for Candida parapsilosis of 0.002 mg/L and 2 mg/L, respectively). Both infants 
were enrolled with candidemia and received 19 days and 16 days of study drug, respectively, 
before discontinuing treatment. The estimated duration of persistent fungal infection was 36 days 
and 35 days, respectively. MICs for the follow-up isolates collected on day 19 for both MCA-
treated infants did not increase (CLSI MIC value of 1 mg/L and EUCAST 1 mg/L and 0.25 
mg/L). One of 2 MCA-treated infants was diagnosed on day 19 with end-organ dissemination to 
the CNS/brain based on head ultrasound, which revealed coagulation in ventricles and nodules 
consistent with fungal sepsis.  
 Similarly, infants in the AmB-D group with persistent infection due to Candida glabrata 
and Candida albicans were treated for baseline candidemia with 11 days and 10 days of study 
drug before discontinuing treatment. The estimated duration of persistent fungal infection was 21 
days and 19 days, respectively. The MIC values of both baseline isolates (1 mg/L CLSI 
methodology and 0.5 mg/L EUCAST methodology) were at the CLSI and EUCAST 
susceptibility breakpoint of 1 mg/L. The infant with Candida glabrata had subsequent isolates 
with identical MICs to baseline. This infant also had end-organ dissemination to the peritoneal 
cavity diagnosed on day 15. Similarly, the infant with Candida albicans candidemia had follow-
up cultures on day 9 but MICs had not changed from baseline (1 mg/L CLSI method and 0.25 
mg/L and 0.5 mg/L for EUCAST methodology). This infant was also diagnosed on day 11 with 
end-organ dissemination in the bowel. 
Five (17%) infants had isolated candiduria at enrollment (MCA, n=3 [15%]; AmB-D, 
n=2 [20%]). All infants responded to treatment except 1 MCA-treated infant, who had 1 positive 
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urine culture (negative blood culture) 3 days before starting MCA. Ten MCA doses were 
administered before discontinuation per physician decision. No urine cultures were reported after 
starting MCA and so the response was not assessable (i.e., ruled a failure). Both of the other 
MCA-treated infants had no growth on follow-up urine cultures. 
 Emergent fungal infection was observed in 1 (5%) MCA-treated infant during study 
treatment. This involved an infection of the urinary tract by a Candida spp. The isolate was not 
sent to the central laboratory; therefore, identification of the species could not be confirmed. No 
recurrent infections were observed in MCA-treated infants throughout the study; however, 
recurrent infection with the same species (Candida glabrata) was noted in 1 (10%) AmB-D-
treated infant which was present 1 week after the end of treatment with a localized urinary tract 
infection (UTI). FFS in infants with baseline end-organ dissemination was achieved in 3 of 7 
(43%; 95% CI, 10–82%) MCA-treated infants and 1 of 3 (33%; 95% CI, 1–91%) AmB-D-treated 
infants, both at the end of study drug therapy and 1 week after the last dose of study drug. 
Pharmacokinetics 
A population PK model was developed using data from this and 8 other studies (data on file at 
Astellas). A two-compartment model with body weight-based allometric scaling and first-order 
elimination adequately described micafungin PK data regardless of age. In the present study, PK 
data were collected from 12 of 30 study participants (Table 2). The mean AUCss and C2h of 
MCA were 399.3 ± 163.9 µg·h/mL (95% prediction interval [PI]: 190.3–742.3 µg/mL) and 31.1 
± 10.5 µg/mL (95% PI: 17.0–49.7 µg/mL), respectively, for the 12 participants in the present 
study. All exposures following MCA 10 mg/kg/day were above the AUC PD target exposure of 
170 µg·h/mL. 
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Safety Outcomes 
Overall, 18 (90%) and 9 (90%) of MCA- and AmB-D-treated infants, respectively, experienced 
≥1 TEAE, with 11 (55%) MCA-treated infants and 5 (50%) AmB-D-treated infants experiencing 
a TEAE considered by investigator assessment to be possibly or probably related to study drug 
(Table 3). The most common TEAEs (irrespective of relatedness to study drug) were anemia 
(MCA: n = 9 [45%]; AmB-D: n = 3 [30%]) and thrombocytopenia (MCA: n = 2 [10%]; AmB-D: 
n = 3 [30%]). In all MCA-treated infants and 1 of 3 AMB-D-treated infants thrombocytopenia 
was resolved. Of the 2 AMB-D-treated infants that did not resolve the thrombocytopenia, 1 was 
not fungal free at 1 week after the end of therapy. The frequency, nature, and severity of 
individual TEAEs were mostly similar between groups. At least 1 serious AE (SAE) occurred in 
12 (60%) and 7 (70%) MCA-treated and AmB-D-treated infants, respectively, with anemia being 
the most common SAE in the MCA group (n = 4 [20%]). All cases of anemia resolved. Three 
(15%) MCA-treated infants and 1 (10%) AmB-D-treated infant died during the study. Deaths in 
the MCA group were attributed to gastrointestinal necrosis, cardiovascular insufficiency, and 
septic shock following sepsis reported at baseline (n = 1 for each, estimated gestation age [EGA] 
at birth: 22 weeks, 26 weeks, and 28 weeks, respectively). One death in the AmB-D group (EGA 
at birth: 24 weeks) was attributed to necrotizing enterocolitis. The investigators reported that 
none of the deaths in either group were considered to be related to the study drug.   
 Changes in hematology and biochemistry parameters from baseline are shown in Table 4. 
Bilirubin and alanine transaminase levels were elevated in a greater proportion of the MCA 
group. Electrolyte supplementation was received by 6 (30%) MCA-treated infants and by 5 
(50%) AmB-D-treated infants (potassium supplementation: n = 2 [10%] and n = 3 [30%], and 
magnesium supplementation: n = 3 [15%] and n = 2 [20%], respectively).  
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DISCUSSION 
Despite the study being terminated early due to poor recruitment, the key finding was that more 
than half of infants with IC including candidemia responded to treatment with MCA or AmB-D 
(60% vs. 70%, respectively), as assessed by the primary endpoint of FFS at 1 week after the last 
dose of study drug. Consistent with the small sample size in each treatment arm, the 95% CIs of 
the point estimates of infants in each group who responded to treatment were wide but 
overlapped. The proportions of infants with a successful clinical response following MCA or 
AmB-D (61% vs. 70%, respectively) were similar to the primary endpoint of FFS 1 week after 
last dose of study drug. Although the low sample number makes interpretation of the data 
difficult, efficacy in the treatment of IC and candidemia was observed in both the MCA and 
AmB-D groups, regardless of fungal species, infection site, age, gender, race, gestational age, or 
geographic region of the infant. A smaller percentage of MCA-treated infants achieved a 
mycological response at end of study drug therapy and 1 week after the last dose of study drug 
compared with AmB-D infants. However, mycological failure in 7 of the 9 MCA-treated infants 
was attributable to a lack of assessment of mycological response, whereas, in all AmB-D-treated 
infants, mycological failure was indicative of persistent fungal infection. All 7 MCA-treated 
infants not assessed for mycological response were alive at 1 week after the last dose, with 3 of 
the 7 having at least 1 negative culture (the study required 2 negative cultures for confirmation of 
eradication).  
Persistent Candida infections due to Candida parapsilosis in 2 MCA-treated infants, and 
Candida glabrata and Candida albicans in AmB-D-treated infants (n=1 for each) were 
documented. Candida parapsilosis is responsible for one quarter of invasive fungal infection 
cases in very low birthweight infants (<1500 g),
30
 and has emerged as the most common non-
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albicans Candida species in neonatal IC.
31
 Though the suitability of the echinocandins for 
clinical management of Candida parapsilosis is uncertain due to higher MICs compared with 
other Candida species,
7
 there was no discernible difference in the frequency and species of 
persistent fungal infections in the present study. 
 High rates of survival and successful treatment responses to MCA among patients aged 
<18 years with IC have been reported in prospective, observational studies.
32,33
 Success rates in 
pediatric studies are similar to the findings of our study in infants. For example, in a pediatric 
sub-study from a randomized, double-blind study comparing MCA (2 mg/kg) with liposomal 
amphotericin B (3 mg/kg) in patients aged <16 years with IC, the investigators reported similar 
treatment success rates following MCA (defined as both a clinical and mycological response at 
the end of therapy; 73% compared with 76% for liposomal amphotericin B).
34
  
 The population PK model that was developed to define the PK of MCA showed that the 
weight-adjusted CL was higher in infants than in older pediatric patients, possibly due to the fact 
that CL per individual increased less than proportionally to the weight increase.
18,20,35
 MCA at 
dosages of as much as 10 mg/kg demonstrate linear PK and favorable tolerability in infants (<4 
months of age), while also providing exposure levels adequate for CNS coverage.
18-20,27,35,36
 This 
is supported by the fact that the systemic plasma exposure at 10 mg/kg in infants was predicted 
to exceed that shown to result in antifungal activity in the cerebrum and cerebellum of a rabbit 
model (AUC0-24, 170 µg·h/mL).  
Previous studies using MCA 10 mg/kg IV in the neonatal population demonstrated that 
this dosage confers plasma exposure to safely treat HCME.
19,20
 The range of weights of infants 
with candidemia within this study were well within the population that can safely receive the 10 
mg/kg dosage of MCA. 
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 Generally, MCA and AmB-D demonstrated acceptable tolerability, with no notable 
differences between groups reported when individual AEs and SAEs were compared. There was 
a slightly greater degree of nephrotoxicity at >25% baseline caused by AmB-D,  although AmB-
D-induced nephrotoxicity, defined as elevated serum creatinine, in the infant is usually 
reversible.
37
 In understanding the relative tolerability of AmB-D in infants within the neonatal 
intensive care unit compared with older children, there are several hypotheses, including a 
greater nephronal reserve or the attention to appropriate hydration in the intensive care unit.
38
 
While nephrotoxicity may be more limited in infants compared with that observed in older 
children, tubular toxicity is a problem associated with AmB-D in both populations.
39
 Evidence 
also exists to support the safety of MCA up to 10 mg/kg in the pediatric patient population as, for 
example, a systematic review of 9 clinical trials in premature and non-premature infants <2 years 
of age found that treatment-related TEAEs were reported in only 23% of patients and did not 
differ between premature and non-premature infants.
40
 Although the rate of TEAEs and 
treatment-related TEAEs in the MCA arm of the current study were higher than those historic 
data, interpretation is limited by the low enrolment in this study, and may reflect in part 
differences in treatment dose and duration compared with those studies. 
Candida UTIs are commonly present in neonatal candidemia. Preclinical models and 
clinical observations demonstrate that echinocandins are able to eradicate Candida spp. causing 
renal candidiasis, reflecting their relatively high concentrations in renal parenchyma.
41-43
 
Although only a small fraction of a circulating echinocandin is typically excreted in the urine, 
sufficiently high urinary concentrations above the MIC of most isolates are achieved to 
successfully treat Candida lower UTIs.
44,45
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A major limitation of the study was, of the planned recruitment of 225 infants, only 30 
infants were enrolled and received the study drug, thereby preventing inferential statistical 
comparisons to establish the noninferiority of MCA compared with AmB-D for the treatment of 
neonatal IC. Therefore, interpretation of the results presented is based on a descriptive summary 
of the findings according to treatment group.  
Recruitment was substantially impacted by the low incidence of fungal infection in this 
patient population. This was due to the use of preventative measures associated with a decreasing 
incidence of IC in neonatal intensive care units, including fluconazole or nystatin prophylaxis, 
and improvements in infection control that have—more generally—reduced nosocomial 
infections in neonatal intensive care unit patients.
46
  
 Furthermore, several other factors contributed to the low patient enrollment. Seventy-one 
of 597 (12%) global investigational sites contacted by the Sponsor agreed to participate. Of the 
71 planned sites, 66 sites were not able to enroll any infants. Recruitment of the small target 
population was further impacted by local ethics committee and/or country-specific restrictions 
relating to conducting pediatric studies at the institution, the comparator used and the safety 
profile of the comparator, the product label for both micafungin and comparator, and the risks 
associated with each compound. The use of AmB-D in place of liposomal amphotericin B or 
fluconazole was frequently denied per local clinical practice, possibly due to perceptions of 
improved safety despite the adverse effects of AmB-D, nephrotoxicity in particular, being less 
than those in older children and adults.
47
 In addition, the efficacy and safety of AmB-D are not 
well established in this patient population, and the micafungin dose (10 mg/kg) proposed in this 
study is higher than the dose approved at the time of the study in Europe (2–4 mg/kg) for 
pediatric patients including infants, with limited safety data available for this dosage level. The 
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approved MCA dose in Europe has subsequently been amended to include higher dosages to 
treat IC (4–10 mg/kg) in infants <4 months of age. Results for the current study show that MCA 
at a daily dose of 10 mg/kg was well tolerated. This finding is consistent with other published 
safety findings of MCA in infants.
20
 
 In conclusion, this study found that infants with IC including candidemia who were 
treated with MCA achieved numerically similar FFS and clinical response to those infants 
treated with AmB-D. Both agents appeared to be safe and well tolerated. These results must be 
interpreted with caution due to low enrollment into the study and the subsequent loss of 
statistical power required for inferential statistical testing. 
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SDC Legend: 
Supplemental Digital Content 1. Patient demographics and baseline characteristics (full 
analysis set) 
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TABLE 1. Efficacy outcomes (full analysis set) 
Efficacy parameter, n/N (%) MCA AmB-D 
Primary Efficacy Outcome   
Fungal-free survival 
12/20 (60) 
(95% CI, 36–81%) 
7/10 (70) 
(95% CI, 35–93%) 
Secondary Efficacy Outcomes   
Clinical response* 
At 1 week after last dose of study drug 
  
Complete 10/18 (56) 7/10 (70) 
Partial 1/18 (6) 0 
Stable 1/18 (6) 1/10 (10) 
Progression 1/18 (6) 2/10 (20) 
Missing 5/18 (28) 0 
End of study†   
Complete 10/18 (56) 7/10 (70) 
Partial 1/18 (6) 0 
Stable 1/18 (6) 1/10 (10) 
Progression 3/18 (17) 2/10 (20) 
Missing 3/18 (17) 0 
Mycological response   
At 1 week after last dose of study drug   
Continuing eradication/eradication 11/20 (55) 8/10 (80) 
Persistence 2/20 (10)‡ 2/10 (20)§ 
Not assessed 7/20 (35)¶ 0 
End of study†   
Eradication 11/20 (55) 8/10 (80) 
Persistence 2/20 (10)‡ 2/10 (20)§ 
Not assessed 7/20 (35)¶ 0 
Emergent fungal infections through end of studyǁ 1/20 (5)# 0 
Recurrent fungal infections through end of 
study** 
0/11 (0) 1/8 (13)†† 
 
*Includes infants with clinical signs and symptoms related to the fungal infection at baseline. 
Two MCA-group infants did not have clinical signs and symptoms at baseline. 
†At 30 days after last dose of study drug. 
‡Candida parapsilosis. 
§Candida albicans and Candida glabrata. 
¶3 of 7 MCA-group infants who were not assessed had 1 negative culture but no repeat. 
ǁEmergent infection defined as a non-Candida infection at any time during the study or a 
Candida infection (other than those detected at baseline) that was detected after 96 hours of 
receiving the first study drug dose. 
#Emergent infection observed with Candida spp. not otherwise specified on Day 6 of the study 
in the urinary tract.  
**Recurrent infection defined as a systemic fungal infection in an infant with eradication at the 
end of the study drug therapy who developed positive blood cultures or a mycologically 
confirmed deep-seated Candida infection, with the same species as the enrolling infection.  
††Recurrent infection with Candida glabrata identified in the urinary tract a week after the last 
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dose in an infant treated for 7 days. 
AmB-D indicates amphotericin B deoxycholate; CI, confidence interval; MCA, micafungin. 
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TABLE 2. Summary of individual pharmacokinetic parameters and exposure 
parameters of MCA 10 mg/kg  
 
Patient age 
group 
N 
PK parameter, mean ± SD (95% prediction interval*) 
CL 
(L/h) 
CL 
(mL/min/kg) 
Vss 
(L/kg) 
t1/2 
(h) 
AUCss
† 
(µg·h/mL) 
C2h
† 
(µg/mL) 
Infants 
(current 
study) 
12 
0.068 ± 
0.039 
(0.022 – 
0.147) 
0.487 ± 
0.200 
(0.225 – 
0.876) 
0.480 ± 
0.159 
(0.306 – 
0.799) 
12.25 ± 
2.87 
(7.51 – 
16.92) 
399.32 ± 
163.88 
(190.33 – 
742.30) 
31.06 ± 
10.53 
(17.01 – 
49.69) 
Infants 
2 days–<4 
months 
64 
0.063 ± 
0.037 
(0.018 – 
0.168) 
0.645 ± 
0.371 
(0.225 – 
1.809) 
0.519 ± 
0.262 
(0.259 – 
1.322) 
10.22 ± 
2.82 
(7.08 – 
16.92) 
322.11 ± 
155.38 
(92.15 – 
742.30) 
28.03 ± 
9.96 
(12.13 – 
49.88) 
*95% prediction interval: 2.5–97.5% range. 
†Infants: AUCss and C2h at dose of 10 mg/kg 2-hour infusion. 
AUCss indicates area under the curve at steady state; C2h, steady-state plasma 
concentration at the end of 2-hour infusion; CL, total body clearance; MCA, micafungin; 
SD, standard deviation; t1/2, half-life; Vss, volume of distribution at equilibrium. 
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TABLE 3. Summary of adverse events (safety analysis set) 
 
Safety parameter, n (%) MCA (N = 20) AmB-D (N = 10) 
TEAEs 18 (90) 9 (90) 
Drug-related TEAEs* 11 (55) 5 (50) 
Serious TEAEs 12 (60) 7 (70) 
Drug-related serious TEAEs* 6 (30) 1 (10) 
Deaths† 3 (15) 1 (10) 
Drug-related TEAEs leading to death* 0 0 
TEAEs by MedDRA system organ class  
occurring in >10% of infants 
  
Blood and lymphatic system disorders 10 (50) 6 (60) 
Infections and infestations 11 (55) 3 (30) 
General disorders and administration site 
conditions 
3 (15) 
 
5 (50) 
 
Investigations 5 (25) 3 (30) 
Vascular disorders 3 (15) 3 (30) 
Metabolism and nutrition disorders 1 (5) 2 (20) 
Respiratory, thoracic, and mediastinal  
disorders 
0 
 
3 (30) 
 
Skin and subcutaneous tissue disorders 1 (5) 2 (20) 
*Possible or probable, as assessed by the Investigator. 
†All deaths reported from the study. 
AmB-D indicates amphotericin B deoxycholate; MCA, micafungin; MedDRA, Medical 
Dictionary for Regulatory Activities (v.12.0); TEAE, treatment-emergent adverse event. 
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TABLE 4. Summary of clinical laboratory test findings (safety analysis set)  
 
Laboratory parameter, n/N (%)* 
MCA 
(N = 20)† 
AmB-D 
(N = 10) 
ALT >3 x ULN‡ 3/17 (18) 1/10 (10) 
AST >3 x ULN‡ 3/17 (18) 2/9 (22) 
Total bilirubin >2 x ULN‡ 7/17 (41) 1/10 (10) 
ALT or AST >3 x ULN and total bilirubin >2 x ULN§ 3/17 (18) 1/10 (10) 
Serum creatinine increase¶   
>25% 6/19 (32) 5/10 (50) 
>50% 3/19 (16) 2/10 (20) 
>100% 2/19 (11) 0 
*The denominator was the number of subjects who had at least 1 non-missing value 
post-baseline. 
†1 patient was withdrawn due to increases in liver function tests.  
‡Values assessed through end of study and include changes at any time during the 
study, regardless of the baseline value.  
§Combination of values measured ≤72 hours. 
¶Post-baseline increase. The denominator was the number of subjects who had a 
baseline value and at least 1 post-baseline value. 
ALT inidicates alanine transaminase; AmB-D, amphotericin B deoxycholate; AST, 
aspartate aminotransferase; MCA, micafungin; ULN, upper limit of normal.  
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